ZA943241B - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
ZA943241B
ZA943241B ZA943241A ZA943241A ZA943241B ZA 943241 B ZA943241 B ZA 943241B ZA 943241 A ZA943241 A ZA 943241A ZA 943241 A ZA943241 A ZA 943241A ZA 943241 B ZA943241 B ZA 943241B
Authority
ZA
South Africa
Prior art keywords
pct
optionally substituted
alkyl
sec
formula
Prior art date
Application number
ZA943241A
Other languages
English (en)
Inventor
Paul John Harris
David John Heal
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of ZA943241B publication Critical patent/ZA943241B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA943241A 1993-05-12 1994-05-11 Therapeutic agents ZA943241B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939309749A GB9309749D0 (en) 1993-05-12 1993-05-12 Therapeutic agents

Publications (1)

Publication Number Publication Date
ZA943241B true ZA943241B (en) 1994-11-14

Family

ID=10735317

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA943241A ZA943241B (en) 1993-05-12 1994-05-11 Therapeutic agents

Country Status (29)

Country Link
US (1) US5652271A (xx)
EP (1) EP0715620B1 (xx)
JP (2) JP3606326B2 (xx)
KR (1) KR100295264B1 (xx)
AT (1) ATE172719T1 (xx)
AU (1) AU681669B2 (xx)
BG (1) BG61913B1 (xx)
BR (2) BR9406577A (xx)
CZ (1) CZ290711B6 (xx)
DE (1) DE69414264T2 (xx)
DK (1) DK0715620T3 (xx)
ES (1) ES2124411T3 (xx)
FI (1) FI955429A (xx)
GB (1) GB9309749D0 (xx)
HU (1) HU211124A9 (xx)
IL (1) IL109635A (xx)
LV (1) LV11320A (xx)
MY (1) MY110773A (xx)
NO (1) NO305165B1 (xx)
NZ (1) NZ266776A (xx)
PH (1) PH30418A (xx)
PL (1) PL176400B1 (xx)
RO (1) RO115519B1 (xx)
RU (1) RU2135467C1 (xx)
SK (1) SK281257B6 (xx)
TW (1) TW318833B (xx)
UA (1) UA42722C2 (xx)
WO (1) WO1994026704A1 (xx)
ZA (1) ZA943241B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
GB9915617D0 (en) * 1999-07-05 1999-09-01 Knoll Ag Therapeutic agents
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
WO2007125913A1 (ja) * 2006-04-26 2007-11-08 Toyama Chemical Co., Ltd. アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
MX369315B (es) 2013-10-07 2019-11-05 Impax Laboratories Inc Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
NO305165B1 (no) 1999-04-12
BR1100306A (pt) 2002-04-02
EP0715620B1 (en) 1998-10-28
NZ266776A (en) 1998-02-26
NO954542L (no) 1996-01-10
WO1994026704A1 (en) 1994-11-24
HU211124A9 (en) 1995-10-30
DE69414264T2 (de) 1999-03-25
AU681669B2 (en) 1997-09-04
GB9309749D0 (en) 1993-06-23
KR100295264B1 (ko) 2001-09-17
JP3606326B2 (ja) 2005-01-05
UA42722C2 (uk) 2001-11-15
RO115519B1 (ro) 2000-03-30
PH30418A (en) 1997-05-09
ES2124411T3 (es) 1999-02-01
JPH08510222A (ja) 1996-10-29
JP2004331669A (ja) 2004-11-25
IL109635A (en) 1998-03-10
FI955429A (fi) 1996-01-03
AU6843394A (en) 1994-12-12
TW318833B (xx) 1997-11-01
IL109635A0 (en) 1994-11-11
SK281257B6 (sk) 2001-01-18
US5652271A (en) 1997-07-29
BR9406577A (pt) 1996-01-30
PL176400B1 (pl) 1999-05-31
FI955429A0 (fi) 1995-11-10
RU2135467C1 (ru) 1999-08-27
SK140795A3 (en) 1996-09-04
PL311628A1 (en) 1996-03-04
BG100127A (bg) 1996-07-31
DK0715620T3 (da) 1999-07-05
LV11320A (lv) 1996-06-20
BG61913B1 (bg) 1998-09-30
EP0715620A1 (en) 1996-06-12
DE69414264D1 (de) 1998-12-03
ATE172719T1 (de) 1998-11-15
CZ293695A3 (en) 1996-06-12
MY110773A (en) 1999-03-31
CZ290711B6 (cs) 2002-09-11
NO954542D0 (no) 1995-11-10

Similar Documents

Publication Publication Date Title
BR9307387A (pt) Agentes terapêuticos
FR2734816B1 (fr) Nouveaux aryl (alkyl) propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9705428D0 (en) Therapeutic agents
FI961630A0 (fi) Terapeuttisia aineita
ZA943241B (en) Therapeutic agents
PL312251A1 (en) Isoquinoline derivatives as therapeutic agents
JO1809B1 (en) Therapeutic agents
CA2162706A1 (en) 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease
IL107486A0 (en) Therapeutic agents